Skip to main content
enGene Holdings Inc. logo

enGene Holdings Inc. — Investor Relations & Filings

Ticker · ENGN ISIN · CA29286M1059 LEI · 529900NE5JFN74BYXQ13 US Manufacturing
Open in API
Filings indexed 224 across all filing types
Latest filing 2026-05-07 Regulatory Filings
Country CA Canada
Listing US ENGN

About enGene Holdings Inc.

https://engene.com/

enGene Holdings Inc. is a clinical-stage biotechnology company developing non-viral gene therapies. The company's proprietary platform is designed for the local delivery of DNA-based immunotherapies directly to mucosal tissues and other organs. Its lead product candidate, EG-70 (detalimogene voraplasmid), is an intravesical therapy being evaluated for the treatment of high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The therapeutic approach aims to stimulate a patient's own immune system to attack tumor cells. By avoiding viral vectors, enGene seeks to create re-dosable genetic medicines that can be administered without the complexities and potential immunogenicity associated with viral-based systems, with the goal of making gene-based treatments more accessible.

Recent filings

Filing Released Lang Actions
8-K - enGene Therapeutics Inc. (0001980845) (Filer)
Regulatory Filings
2026-05-07 English
8-K - enGene Therapeutics Inc. (0001980845) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content includes a corporate name change, amendments to articles of incorporation, and a press release about the name change. There are no financial statements or detailed financial data presented. The document is primarily an announcement of corporate changes and related exhibits. This fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous filings that do not fit other specific categories like Annual Report or Earnings Release. The document length is just over 5,000 characters but contains no substantive financial data or management discussion, so it is not an Annual Report or Interim Report. Therefore, the correct classification is Regulatory Filings (RNS).
2026-04-09 English
S-3 - ENGENE HOLDINGS INC. (0001980845) (Filer)
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 Registration Statement filed with the SEC by enGene Holdings Inc. It is a registration statement under the Securities Act of 1933 for the purpose of registering securities for sale, including common shares, preferred shares, debt securities, subscription receipts, warrants, and units. The document includes detailed information about the offering, the securities, and the registration process. It is not a financial report, earnings release, or management discussion, but a capital markets filing related to fundraising and securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it is the actual registration statement, not just an announcement of a report.
2026-02-19 English
10-K/A - ENGENE HOLDINGS INC. (0001980845) (Filer)
Annual Report FY 2025
2026-02-19 English
SCHEDULE 13G Filing
Major Shareholding Notification
2026-02-17 English
SCHEDULE 13G/A Filing
Major Shareholding Notification
2026-02-17 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.